Physician profile
Thomas S Rives
NPI 1457342370
$4,047.03
in general payments reported to CMS, 2019-2025
41 companies · $838 in 2025
The $838 reported for 2025 was more than what 90% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $79.81 · 2021: $262 · 2022: $813 · 2023: $663 · 2024: $692 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,192.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $834.73 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $538.78 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $283.20 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Abbvie INC. | $216.13 | 2019-2025 | Vraylar |
| Lilly USA, LLC | $152.62 | 2022-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $146.97 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $139.95 | 2019-2022 | |
| Exact Sciences Corporation | $138.29 | 2023-2025 | Cologuard Collection Kit |
| Atricure, INC. | $135.69 | 2022 | |
| Janssen Pharmaceuticals, INC | $118.30 | 2019-2022 | |
| Abbott Laboratories | $103.17 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Daiichi Sankyo INC. | $84.30 | 2021-2024 | Injectafer |
| Mylan Specialty L.P. | $81.88 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $68.26 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $68.21 | 2023-2025 | Gvoke Hypopen |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Rives listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.